Bystander elimination of antigen loss variants in established tumors
- PMID: 14981514
- DOI: 10.1038/nm999
Bystander elimination of antigen loss variants in established tumors
Abstract
Cancers express antigens that are targets for specific cytotoxic T lymphocytes (CTLs). However, cancer cells are genetically unstable. Consequently, sub-populations of cancer cells that no longer express the target antigen may escape destruction by CTLs and grow progressively. We show that cytotoxic T cells indirectly eliminate these antigen loss variants (ALVs) in a model system when the parental cancer cells express sufficient antigen to be effectively cross-presented by the tumor stroma. When the parental tumor expressed lower levels of antigen, cytotoxic T cells eradicated the antigen-positive parental cancer cells, but the ALVs escaped, grew and killed the host. By contrast, when the parental tumor expressed higher levels of antigen, cytotoxic T cells eradicated not only the parental cancer cells but also the ALVs. This 'bystander' elimination of ALVs required stromal cells expressing major histocompatibility complex (MHC) molecules capable of presenting the antigen, and occurred in tumors showing evidence of stromal destruction. ALVs were apparently eliminated indirectly when tumor-specific CTLs killed stromal cells that were cross-presenting antigen produced by and released from antigen-positive cancer cells. These results highlight the general importance of targeting the tumor stroma to prevent the escape of variant cancer cells.
Similar articles
-
Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells.Cancer Immun. 2005 Jun 6;5:8. Cancer Immun. 2005. PMID: 15934727
-
Immune selection in murine tumors. Ph.d thesis.APMIS Suppl. 2003;(106):1-46. APMIS Suppl. 2003. PMID: 12739251
-
IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers.J Clin Invest. 2008 Apr;118(4):1398-404. doi: 10.1172/JCI33522. J Clin Invest. 2008. PMID: 18317595 Free PMC article.
-
MHC class I restricted T cells and immune surveillance against transplanted ultraviolet light-induced tumors.Semin Cancer Biol. 1991 Oct;2(5):321-8. Semin Cancer Biol. 1991. PMID: 1837738 Review.
-
Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms.Semin Cancer Biol. 1991 Oct;2(5):347-54. Semin Cancer Biol. 1991. PMID: 1773050 Review.
Cited by
-
Interleukin-7 Modulates Anti-Tumor CD8+ T Cell Responses via Its Action on Host Cells.PLoS One. 2016 Jul 22;11(7):e0159690. doi: 10.1371/journal.pone.0159690. eCollection 2016. PLoS One. 2016. PMID: 27447484 Free PMC article.
-
Trial watch: Naked and vectored DNA-based anticancer vaccines.Oncoimmunology. 2015 Apr 2;4(5):e1026531. doi: 10.1080/2162402X.2015.1026531. eCollection 2015 May. Oncoimmunology. 2015. PMID: 26155408 Free PMC article.
-
Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer.Cancer Cell. 2011 Dec 13;20(6):755-67. doi: 10.1016/j.ccr.2011.10.019. Cancer Cell. 2011. PMID: 22172721 Free PMC article.
-
In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines.J Clin Invest. 2006 Jul;116(7):1946-54. doi: 10.1172/JCI28045. Epub 2006 Jun 22. J Clin Invest. 2006. PMID: 16794737 Free PMC article.
-
A vaccine that co-targets tumor cells and cancer associated fibroblasts results in enhanced antitumor activity by inducing antigen spreading.PLoS One. 2013 Dec 12;8(12):e82658. doi: 10.1371/journal.pone.0082658. eCollection 2013. PLoS One. 2013. PMID: 24349329 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials